Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 191

Sort by

Sort Order Select

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

DR. Brian Koffman, John M. Pagel, MD PhD DSc, Andy Kaempf, Byung Park, PhD, Liza Avruch, Christopher Lee, PhD MS, Babak Movassaghi, PhD MBA, John C. Byrd, MD, Alan Skarbnik, MD, Matthew S. Davids, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4716.

https://doi.org/10.1182/blood-2019-123579

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends

Anoosha Habibi, Stephanie Ngo, MD, Etienne Audureau, MD PhD, Armand Mekontso-Dessap, MD PhD, Keyvan Razazi, MD, Elena Foïs, MD, Thibaud Damy, MD PhD, France Pirenne, MD PhD, Marc Michel, Vincent Audard, MD PhD, Frédéric Galactéros, MD PhD, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1031.

https://doi.org/10.1182/blood-2019-131304

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

Alison E Meyer, PhD, Cary Stelloh, Joseph B Fisher, PhD, Kirthi Pulakanti, George S. Vassiliou, FRCPath, MRCP, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD, Sridhar Rao, MD PhD

Blood (2019) 134 (Supplement_1): 2515.

https://doi.org/10.1182/blood-2019-126042

Published: 2019

Journal Articles

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Deedra Nicolet, MS, Alice S. Mims, MD, Dimitrios Papaioannou, MD, Christopher J. Walker, PhD, James S. Blachly, MD, Sophia E. Maharry, Andrew J. Carroll, PhD, Richard M. Stone, MD, Bayard L Powell, MD, Albert de la Chapelle, MD PhD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2681.

https://doi.org/10.1182/blood-2019-130076

Published: 2019

Journal Articles

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

Tracy Murphy, MDFRCP,FRCPath, Stanley W.K. Ng, PhD, Tong Zhang, Ian King, PhD, Andrea Arruda, Jaime O. Claudio, PhD, Narmin Ibrahimova, Fiona Ferrera, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, MSc, Brian Leber, MD, Mitchell Sabloff, MD, Mark D. Minden, MD PhD, Tracy L. Stockley, PhD FCCMG, FACMG, Steven M Chan, MD PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 2682.

https://doi.org/10.1182/blood-2019-130532

Published: 2019

Journal Articles

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Giovanni Marconi, Roberta di Nicola, Chiara Sartor, MD, Mariachiara Abbenante, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Sarah Parisi, MD PhD, Carmen Baldazzi, PhD, Maria Chiara Fontana, PhD, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli, MD, Michele Baccarani, MD, Cristina Papayannidis, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2617.

https://doi.org/10.1182/blood-2019-130630

Published: 2019

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Blood (2019) 134 (Supplement_1): 2591.

https://doi.org/10.1182/blood-2019-127253

Published: 2019

Journal Articles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Ashwini M Patil, MSc, Stefanie Kesper, Vishal Khairnar, PhD, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, PD, MD

Blood (2019) 134 (Supplement_1): 2537.

https://doi.org/10.1182/blood-2019-125331

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 5619.

https://doi.org/10.1182/blood-2019-125286

Published: 2019

Journal Articles

Impact of Modifying Conditioning and Immunosuppressive Strategies in Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia

Nawar Dakhallah, MD, Mylène Beauchemin, Johanne Richer, Sonia Cellot, MD PhD, Pierre Teira, MD, Michel Duval, MD, Henrique Bittencourt

Blood (2019) 134 (Supplement_1): 5714.

https://doi.org/10.1182/blood-2019-122988

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Combinatorial Genetics Uncovers Novel Targets for the Treatment of Npm1/Cohesin Mutated AML

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Impact of Modifying Conditioning and Immunosuppressive Strategies in Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only